Clinical Trial Update: Early Post-marketing Study of Eliquis (Apixaban)

View source ↗

Summary

The trial update notes that an early post-marketing study of Eliquis (apixaban) for non-valvular atrial fibrillation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-valvular Atrial Fibrillation

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-valvular Atrial Fibrillation (NVAF) | Status: WITHDRAWN